Biological
RIX4414 vaccine clinical trials
Also written Rotarix.
How studies write it
Studies that test it under each name
Name
Brand
- Rotarix
- 28
Studies by the year they started
32 studies that test it; most in 2007 (8)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2003 | 2 |
| 2005 | 3 |
| 2006 | 1 |
| 2007 | 8 |
| 2008 | 1 |
| 2009 | 3 |
| 2010 | 2 |
| 2011 | 2 |
| 2012 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2021 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 11
GlaxoSmithKline (21) · PATH (2) · Telethon Kids Institute (1) · Centre for Infectious Disease Research in Zambia (1) · University of Vermont (1) · National Institute of Pediatrics, Mexico (1) · Children's Hospital Medical Center, Cincinnati (1) · National Institute of Hygiene and Epidemiology, Vietnam (1)
Often tested with
Tested in the same studies.
Diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine (3) · RotaTeq (3) · PHiD-CV vaccine (2) · Diphtheria-Tetanus-Pertussis Vaccine (1) · Hepatitis B Vaccines (1) · Acetaminophen (1)
Studies
Open first, then newest update. How each study uses RIX4414 vaccine is read from its arms, and is right about nine times in ten.
Testing it · 32
- Human Challenge With Live-attenuated Rotavirus to Assess Next-generation Rotavirus Vaccines in AfricaCompletedPhase 2Centre for Infectious Disease Research in ZambiaNCT04658914Written as Rotarix
- Exploration of the Biologic Basis for Underperformance of Oral Polio and Rotavirus Vaccines in BangladeshCompletedPhase 3University of VermontNCT01375647Written as Rotarix
- Optimising Rotavirus Vaccine in Aboriginal ChildrenActive, not recruitingPhase 4Telethon Kids InstituteNCT02941107Written as Rotarix (RV1)
- Mixed Schedule Study of Live Oral Rotavirus Vaccines and Trivalent P2-VP8 Subunit Rotavirus VaccineCompletedPhase 2PATHNCT04344054Written as Rotarix
- A Study of Safety, Reactogenicity and Immunogenicity of HRV Vaccine in HIV Infected Infants in South AfricaCompletedPhase 2GlaxoSmithKlineNCT00263666Written as Rotarix
- Study to Evaluate Immunogenicity, Reactogenicity and Safety of Rotarix™ Vaccine in Korean InfantsCompletedPhase 4GlaxoSmithKlineNCT00969228Written as Rotarix ™
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 12wks of AgeCompletedPhase 3GlaxoSmithKlineNCT00489554Written as Rotarix
- A Study to Evaluate Immune Response and Safety of Two Doses of GSK Biologicals' HRV Liquid Vaccine in Healthy Infants.CompletedPhase 2GlaxoSmithKlineNCT00432380Written as Rotarix™
- Efficacy, Safety, Reactogenicity & Immunogenicity of the Rotarix Vaccine in Japanese InfantsCompletedPhase 3GlaxoSmithKlineNCT00480324Written as Rotarix
- Evaluate Protective Efficacy of Diff Strengths of Human Rotavirus Vaccine After Admn of 2 Doses to Infants Aged 2 MonthsCompletedPhase 2GlaxoSmithKlineNCT00385320Written as HRV vaccine
- Evaluation of Immunogenicity and Safety of the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus (DPT-IPV) Vaccine Squarekids Co-administered With GSK Biologicals' Human Rotavirus (HRV) Vaccine Rotarix (GSK444563) in Healthy InfantsCompletedPhase 4GlaxoSmithKlineNCT02907216Written as Rotarix
- Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.CompletedPhase 3GlaxoSmithKlineNCT00420316Written as Rotarix (primary vaccination study)
- Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention ProgramsCompletedPhase 3National Institute of Pediatrics, MexicoNCT02193061Written as Rotarix
- Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot StudyCompletedPhase 4Children's Hospital Medical Center, CincinnatiNCT02542462Written as Rotarix®,
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6 to 8 Weeks of AgeCompletedPhase 3GlaxoSmithKlineNCT00533507Written as Rotarix
- To Assess Safety, Reactogenicity & Immunogenicity of 2 Doses of GSK's Oral Human Rotavirus Vaccine in Pre-Term InfantsCompletedPhase 3GlaxoSmithKlineNCT00420745Written as Rotarix™
- Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to InfantsCompletedPhase 3GlaxoSmithKlineNCT00158756Written as Rotarix™
- A Study to Explore the Existence of Horizontal Transmission of the RIX4414 Vaccine Strain Between Twins Within a Family.CompletedPhase 3GlaxoSmithKlineNCT00396630Written as Rotarix
- Study to Evaluate the Safety of Rotarix™ in Chinese ChildrenCompletedPhase 1GlaxoSmithKlineNCT01086436Written as Rotarix ™
- Study to Evaluate the Reactogenicity and Safety of Rotarix™ in Chinese AdultsCompletedPhase 1GlaxoSmithKlineNCT01162590Written as Rotarix ™
See all 32 studies that test RIX4414 vaccine →
Given in every arm · 16 — RIX4414 vaccine is usual care beside what is tested
- Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT03621670Written as Rotarix
- Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824194Written as Rotarix
- Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of AgeActive, not recruitingPhase 3SanofiNCT06824181Written as Rotarix
- Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in ThailandCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT04429295Written as Human Rotavirus, live attenuated
- Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine in Infants and Toddlers When Administered Concomitantly With Routine Pediatric Vaccines in the United KingdomCompletedPhase 3Sanofi Pasteur, a Sanofi CompanyNCT03632720Written as Human rotavirus RIX4414 strain vaccine
- Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)CompletedPhase 3Merck Sharp & Dohme LLCNCT04031846Written as Rotarix™
- This Study Will Evaluate the Immunogenicity, Reactogenicity and Safety of the Routine Infant Vaccines Pediarix®, Hiberix® and Prevenar 13® When Co-administered With GlaxoSmithKline (GSK) Biologicals' Liquid Human Rotavirus Vaccine (HRV) as Compared to GSK's Licensed Lyophilized VaccineCompletedPhase 3GlaxoSmithKlineNCT03207750Written as Rotarix
- Immunogenicity and Safety of GlaxoSmithKline Biologicals' Infanrix™-IPV+Hib VaccineCompletedPhase 3GlaxoSmithKlineNCT01309646Written as Rotarix™
- Study to Determine the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals; Infanrix Hexa at 2, 4 and 6 Months of Age in Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT02096263Written as Rotarix
- Immunogenicity, Safety and Reactogenicity Study of GlaxoSmithKline (GSK) Biologicals' Hib-MenCY-TT (MenHibrix®) Vaccine Compared to Merck & Co, Inc. PedvaxHIB Vaccine in Healthy Infants and Toddlers 12 to 15 Months of AgeCompletedPhase 3GlaxoSmithKlineNCT01978093Written as Rotarix®
- Study of GlaxoSmithKline Biologicals' GSK2202083A Vaccine in Healthy InfantsCompletedPhase 2GlaxoSmithKlineNCT01090453Written as Rotarix™
- Primary Vaccination Study With a Pneumococcal Conjugate Vaccine in Healthy Children 6-12wks of AgeCompletedPhase 3GlaxoSmithKlineNCT00808444Written as Rotarix
- Primary and Booster Vaccination Study With a Pneumococcal Vaccine in HIV Infected, HIV Exposed Uninfected and HIV Uninfected Children 6 to 10 Weeks of Age.CompletedPhase 3GlaxoSmithKlineNCT00829010Written as Rotarix
- Consistency & Immunogenicity Study of 3 Lots of GSK's Hib Conjugate Vaccine Versus ActHIB & Pentacel in Healthy InfantsCompletedPhase 3GlaxoSmithKlineNCT01000974Written as Rotarix™
- Study of a Birth Dose of GlaxoSmithKline Biologicals' 251154 VaccineWithdrawnPhase 2GlaxoSmithKlineNCT01110044Written as Rotarix™
- Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV VaccineStatus unknownPhase 4University of ChileNCT01841671Written as Rotarix
As the comparator · 5 — what is tested is compared with RIX4414 vaccine
- A Trial to Assess the Safety, Immunogenicity and Efficacy of a Trivalent Rotavirus P2-VP8 Subunit Vaccine in Prevention of Severe Rotavirus Gastroenteritis in Healthy Infants in Africa and IndiaRecruitingPhase 3PATHNCT04010448Written as Rotarix
- Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 WeeksCompletedPhase 3GlaxoSmithKlineNCT06025695Written as GSK's liquid oral live attenuated HRV
- Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in ZambiaCompletedPhase 2/3Centre for Infectious Disease Research in ZambiaNCT03602053Written as Rotarix®
- Evaluation of Immunogenicity and Safety of Two Formulations of GSK Biologicals' Human Rotavirus (HRV) Vaccine (444563), in Healthy Infants Starting at Age 6-12 WeeksCompletedPhase 3GlaxoSmithKlineNCT02914184Written as Rotarix
- Safety and Immunogenicity of MT-5625 in Healthy Adults, Toddlers and InfantsCompletedPhase 1Mitsubishi Tanabe Pharma CorporationNCT03507738Written as Rotarix
Codes
What other systems call RIX4414 vaccine · ClinicalTrials.gg INT004703
- RxNorm 805573One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| RxNorm | 805573 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.